Project Name: Breast Analytics Access and Equity of Service Joint Working Project
Joint Working Project Summary: The principle of this joint working project is that the Greater Manchester (GM) secondary breast cancer service could be optimised and perceived variations in access to treatment addressed if an analytical approach to pathway optimisation was conducted. This can be achieved through the analysis of data generated by routine delivery of care for breast cancer services in GM involving The Christie. The project consists of two components, pathway analysis and patient pathway experience. The project will provide a visual representation of the secondary breast cancer service in order to understand the variation of access to breast cancer services that exist to the people of GM and build a case for change that can be shared with operational healthcare leaders in the GM region.
This project will be based around partnership working and the collaborative sharing of insights and expertise between the The Christie and Novartis, with the support of IQVIA, in order to optimise the treatment of secondary breast cancer within Greater Manchester
Expected Patient Outcomes for this Project The capture by patients and remote monitoring by clinicians of patient experience data is increasingly understood to improve the accuracy and timeliness of treatment interventions. As a consequence of the analysis it is anticipated that the NHS gains clarity on where to focus resource effort in order to reduce variation in access to treatment for the affected patient cohorts. It is also expected that by understanding patient experience of the breast cancer service improvements can be made to make that service more responsive to particular patient needs.
Start Date & Duration: December 2017 – October 2018
Project Period: 10 months
Imperial College Healthcare NHS Trust.
Project Name: The Hammersmith Nurse Led Haemoglobinopathy / Iron Over-Load Service Development Project.
Joint Working Project Summary: Hammersmith Hospital, part of the Imperial College Healthcare NHS Trust (“ICHNT”) currently cares for over 400 adult Haemoglobinopathy (sickle cell disease and thalassaemia) / Iron Over-Load (“IOL”) patients, of which around 60 receive regular blood transfusions and require Iron Chelation Therapy (“ICT”). However, there is not a dedicated Red Cell Clinical Nurse Specialist (“CNS”) to care for the adult Haemoglobinopathy / IOL patients.
The principal aims of the joint working project (“JWP”) are to improve the quality of care and the clinic service for adult Haemoglobinopathy / IOL patients by the development and implementation of a new specialist Red Cell CNS led clinic service for adult Haemoglobinopathy / IOL patients.
Expected Patient Outcomes for this Project: The new specialist Red Cell CNS led clinic service for adult Haemoglobinopathy / IOL is expected to provide:
a patient centric clinic service to build engagement and relationships between the CNS and patients/carers;
support for patients/carers to enhance their understanding, encourage a positive approach to their condition and teach effective techniques for self-management in line with current clinical guidelines;
a reduction in waiting times in clinic to see a healthcare professional;
improve patient satisfaction of the clinic service by 25% at 16 months and a further 25% improvement at 28 months.
The NHS will benefit from a new model of care in terms of Red Cell CNS led clinics working alongside medical / Consultant clinics, which will incorporate regular clinical reviews and assessments of Haemoglobinopathy / IOL patients and provide evidence of service improvement and enhanced Haemoglobinopathy / IOL patient satisfaction.
Novartis working in partnership with the NHS will gain a richer understanding of the main elements of treating and caring for Haemoglobinopathy / IOL patients to improve patient care and Haemoglobinopathy / IOL patient satisfaction to help tailor and adapt Novartis support services.
Novartis and the NHS will combine financial resources for the generation of the new Red Cell CNS post. The NHS will develop the CNS training program, service protocol and patient satisfaction questionnaire. Novartis will provide project management documentation and support. A project steering group will regularly review and track the progress and impact of this JWP via the generation of aggregated service level reports.
The progress of the JWP will be tracked to six monthly milestones, with the completion of a series of deliverables, which make up each Milestone, triggering the next Milestone to begin. The results will be included in a JWP summary report and a business case aimed at funding the new service once the JWP comes to an end.
Start Date and Duration: December 2017 with an expected duration to the end of June 2020. Project Period: 30 months